Brady W. Dougan - Jun 12, 2025 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role: Director
Signature: /s/ Brady W. Dougan by Dale A. Sander as Attorney-in-Fact
Stock symbol: HUMA
Transactions as of: Jun 12, 2025
Transactions value $: $0
Form type: 4
Date filed: 6/16/2025, 04:31 PM
Previous filing: Jan 23, 2025
Next filing: Aug 20, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Dougan Brady W	Director	2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM	/s/ Brady W. Dougan by Dale A. Sander as Attorney-in-Fact	2025-06-16	0001878020

Transactions Table

Type	Sym	Class	Shares After	Date	Ownership	Footnotes
holding	HUMA	Common Stock	0	Jun 12, 2025	Direct	F1
holding	HUMA	Common Stock	2.24M	Jun 12, 2025	By Ayabudge LLC	F1
holding	HUMA	Common Stock	244K	Jun 12, 2025	By spouse
holding	HUMA	Common Stock	1.15M	Jun 12, 2025	By The Niklason Living Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HUMA	Stock Options (right to buy)	Award	$0	0		$0.00	0	Jun 12, 2025	Common Stock	80K	$2.41	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This Form 4 amends the previously reported number of shares owned by the Reporting Person and Ayabudge LLC, an entity controlled by the Reporting Person, to correct an error in a Form 4 filed by the Reporting Person on August 21, 2023 (the "Original Form 4"). The Original Form 4 reported the sale of 510,161 shares of common stock of Humacyte, Inc. as a sale by Ayabudge LLC; however, these shares were sold by the Reporting Person.
F2	The first 25% of the option becomes exercisable on June 12, 2026, after which 1/48 of the option will become exercisable on the 12th of each month through June 12, 2029.

Content

This Form 4 amends the previously reported number of shares owned by the Reporting Person and Ayabudge LLC, an entity controlled by the Reporting Person, to correct an error in a Form 4 filed by the Reporting Person on August 21, 2023 (the "Original Form 4"). The Original Form 4 reported the sale of 510,161 shares of common stock of Humacyte, Inc. as a sale by Ayabudge LLC; however, these shares were sold by the Reporting Person.

The first 25% of the option becomes exercisable on June 12, 2026, after which 1/48 of the option will become exercisable on the 12th of each month through June 12, 2029.